Brussels, 09/06/2008 (Agence Europe) - The European Medicines Agency (EMEA) says in a press release published on Thursday 5 June that it has reviewed the risks associated with the use of heparin (used to prevent thrombosis) medicinal products, following the contamination of various batches with oversulphated chondroitin sulphate. This substance caused serious side effects in patients who received injections of unfractionated (standard) heparin. It was also found in low molecular weight...